The in vivo efficacies of
pefloxacin, a new
fluoroquinolone, and
amikacin-
ceftazidime were compared in 50 rabbits with experimental aortic
endocarditis caused by Pseudomonas aeruginosa. Animals were randomly chosen to receive 4 or 10 days of no
therapy (controls),
pefloxacin (40 mg/kg [
body weight] per day, intramuscularly [i.m.]), or
amikacin (30 or 80 mg/kg per day, i.m.)-
ceftazidime (150 mg/kg per day, i.m.).
Pefloxacin and both
amikacin regimens significantly reduced vegetation bacterial densities compared with controls at days 4 and 10 of treatment (P less than 0.0005). By day 10 of
therapy, between 33 and 40% of vegetations from
amikacin-
ceftazidime recipients contained
ceftazidime-resistant bacteria (MICs, greater than 25 micrograms/ml);
nitrocefin agar overlay confirmed that these
ceftazidime-resistant variants were constitutive overproducers of
beta-lactamase. At
therapy days 4 and 10, approximately 30% of vegetations sampled from
pefloxacin recipients contained bacteria for which
pefloxacin MICs were four- to eightfold higher than the MIC for the parental strain used to initially induce
endocarditis (MIC, 0.19 microgram/ml). These variants also exhibited increases in
ciprofloxacin and
ticarcillin MICs, as well as pleotropic resistance to
chloramphenicol (but not to
amikacin,
ceftazidime, or
tetracycline).
Amikacin-
ceftazidime, as well as
pefloxacin, was effective in this model of aortic pseudomonal
endocarditis. However, in vivo development of
ceftazidime resistance and step-ups in
pefloxacin MICs among intravegetation isolates were associated with inability to completely eradicate P. aeruginosa from aortic vegetations.